Fairmount Funds Management

Latest statistics and disclosures from Fairmount Funds Management's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Fairmount Funds Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Fairmount Funds Management

Companies in the Fairmount Funds Management portfolio as of the June 2021 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Insmed Com Par $.01 (INSM) 15.0 $37M +33% 1.3M 28.46
Zogenix Com New (ZGNX) 14.0 $34M +40% 2.0M 17.28
Axsome Therapeutics (AXSM) 8.7 $21M +24% 313k 67.46
Argenx Se Sponsored Adr (ARGX) 8.6 $21M +34% 69k 301.07
Iovance Biotherapeutics (IOVA) 5.4 $13M -10% 506k 26.02
Instil Bio (TIL) 5.4 $13M +22% 674k 19.32
Allakos (ALLK) 5.3 $13M +3% 152k 85.37
Cogent Biosciences (COGT) 5.2 $13M 1.6M 8.11
Amarin Corp Spons Adr New (AMRN) 4.6 $11M +57% 2.5M 4.38
ACADIA Pharmaceuticals (ACAD) 4.2 $10M 424k 24.39
Therapeutics Acquisition Cor Com Cl A 3.6 $8.9M +1628% 864k 10.27
Trillium Therapeutics Com New (TRIL) 3.6 $8.7M -32% 896k 9.70
Catabasis Pharmaceuticals In Com New (CATB) 3.5 $8.6M +7596% 4.1M 2.11
Amicus Therapeutics (FOLD) 3.5 $8.6M +12% 889k 9.64

Setup an alert

Fairmount Funds Management will file the next quarterly 13-HR in about 2 months. Would you like to be notified?

Enanta Pharmaceuticals (ENTA) 3.2 $7.8M +4% 178k 44.01
Global Blood Therapeutics In (GBT) 3.0 $7.4M +20% 210k 35.02
Keros Therapeutics (KROS) 2.6 $6.3M +36% 149k 42.47
Miragen Therapeutics (VRDN) 0.3 $642k 35k 18.29
Verona Pharma Sponsored Ads (VRNA) 0.2 $549k 84k 6.54

Past Filings by Fairmount Funds Management

SEC 13F filings are viewable for Fairmount Funds Management going back to 2019